Enovis (ENOV) FY 2025 Conference June 10, 2025 02:00 PM ET Speaker0 Check, check. So my name's Phil Cooper. I'm part of David Roman's U. Med tech team. We're pleased to be joined by Innovus and we have with us Ben Barry, the CFO. Thank you for coming. Thank I thought we'd start, for those less familiar with the story, a bit of an overview, the history, the spin of ESOP and Innovus separating out rebranding from Colfax would be great. Speaker1 Yeah, sure. We've been through quite a bit of transformation over ...

Enovis (ENOV) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Kyle Rose - Vice President of Investor RelationsMatthew Trerotola - CEO & ChairmanBen Berry - CFOVijay Kumar - Senior Managing DirectorWilliam Plovanic - Managing Director - Equity ResearchDane Reinhardt - Senior Equity Research AssociateJoseph Conway - Equity Research AssociateRussell Yuen - Equity Research AssociateYoung Li - Senior VP - Equity Research Conference Call Participants Vik Chopra - AnalystRobert Marcus - Analyst ...

Enovis (ENOV) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Hello, everyone, and welcome to the Innovus Corporation Q1 twenty twenty five Results Call. My name is Ezra, and I will be your coordinator today. I will now hand you over to your host, Kyle Rose, Vice President of Investor Relations to begin. Please go ahead. Speaker1 Thank you, Ezra. Good morning, everyone, and thank you for joining us today for our first quarter twenty twenty five results conference call. I'm Kyle Rose, Vice President ...

Enovis (ENOV) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.46%. A quarter ago, it was expected that this manufacturing and engineering company would post earnings of $0.92 per share when it actually produced earnings of $0.98, delivering a surprise of 6.52%.Over the last four qua ...

First Quarter 2025 Results May 8, 2025 This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward- looking statements include, but are not limited to, statements concerning Enovis' plans, goals, objectives, outlook, expectations and intentions, and other statements that are not historical or current fact. Forward-looking statements and are based on Enovis' current expectations and i ...

Financial Performance - Enovis reported first-quarter 2025 net sales of $559 million, an 8% increase on a reported basis and 9% on a comparable basis year-over-year[3]. - The net loss from continuing operations for the first quarter was $56 million, representing a loss margin of 10.0%[4]. - Adjusted EBITDA for the first quarter was $99 million, equating to 17.7% of sales, an increase of 160 basis points compared to the prior year[4]. - Reconstructive sales grew 11% year-over-year on a reported basis, while P&R sales increased by 5%[3]. - Enovis Corporation reported a net loss from continuing operations of $55.6 million for the three months ended April 4, 2025, compared to a loss of $71.8 million for the same period in 2024, representing a 22.5% improvement[26]. - Adjusted EBITDA for the same period was $99.2 million, with an adjusted EBITDA margin of 17.7%, up from $83.2 million and 16.1% in the prior year, indicating a 19.5% increase in adjusted EBITDA[26]. - Net sales increased to $558.8 million, a growth of 8.2% from $516.3 million in the previous year, driven by strong performance in both the Prevention & Recovery and Reconstructive segments[33]. Revenue Outlook - Enovis updated its 2025 revenue outlook to a range of $2.22-2.25 billion, up from previous expectations of $2.19-2.22 billion[7]. - Adjusted EBITDA for 2025 is forecasted to be $385-395 million, revised down from $405-415 million due to a $20 million tariff-related impact[7]. - Full-year adjusted earnings per share guidance was updated from $3.10-$3.25 to $2.95-$3.10[7]. Leadership Changes - The company appointed Damien McDonald as CEO, effective May 12, 2025[6]. Strategic Focus - Enovis emphasized a focus on disciplined execution and strategic investment to drive above-market growth[5]. - The company is committed to a multi-year cadence of high-impact product launches across its portfolio[5]. Asset and Liability Management - Total current assets rose to $1,218.2 million as of April 4, 2025, compared to $1,146.4 million at the end of 2024, reflecting a 6.3% increase[30]. - Enovis Corporation's total liabilities increased to $2,254.8 million as of April 4, 2025, from $2,154.4 million at the end of 2024, representing a 4.6% rise[30]. - Cash and cash equivalents decreased to $38.5 million from $48.2 million at the end of 2024, marking a decline of 19.5%[31]. Operational Efficiency - The company reported a net cash used in operating activities of $1.6 million for the three months ended April 4, 2025, a significant improvement from $36.2 million used in the same period last year[32]. - The gross profit margin (GAAP) improved to 59.4% for the three months ended April 4, 2025, compared to 57.7% in the prior year[28]. - The company completed strategic purchases of economic interest on future royalty payments for a total of $43.8 million, with a recognized charge of $35.8 million for the net present value of these purchases[26].

Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April ...

Core Viewpoint - Enovis Corporation will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on May 8, 2025, at 8:30 a.m. Eastern Time, with an earnings press release issued earlier that morning [1]. Group 1: Conference Call/Webcast Information - Investors can access the live webcast via a link on the Enovis website, and those participating in the call can dial (833) 335-0887 using Access Code: 482081 [2]. - A replay of the call will be available on the Enovis website later that day [2]. Group 2: About Enovis - Enovis Corporation is an innovation-driven medical technology growth company focused on developing clinically differentiated solutions that improve patient outcomes and transform workflows [3]. - The company offers a wide range of products, services, and integrated technologies aimed at supporting active lifestyles in orthopedics and beyond [3]. - Enovis shares are listed on the New York Stock Exchange under the symbol ENOV [3]. Group 3: Availability of Information - Enovis routinely announces material information to investors through SEC filings, press releases, public conference calls, webcasts, and its Investor Relations website [4]. - The company encourages investors and the media to review the information shared on its Investor Relations website [4].

Core Points - Enovis Corporation announced the appointment of Damien McDonald as CEO, effective May 12, 2025, succeeding Matt Trerotola who will retire [1][3] - The company expects first quarter revenues to be between $555 million and $563 million, with adjusted EBITDA projected to be between $97 million and $100 million [1][6] Leadership Transition - Sharon Wienbar, Lead Independent Director, expressed enthusiasm for McDonald's appointment, highlighting his strong track record in the medical technology sector [2] - McDonald has over 35 years of experience in the medical device industry, previously serving as CEO of LivaNova, where he improved growth, profitability, and shareholder value [2][3] - Following Trerotola's retirement, Wienbar will assume the role of independent Chair of the Board [3] Company Overview - Enovis Corporation is focused on developing clinically differentiated medical technology solutions aimed at improving patient outcomes [4] - The company emphasizes a culture of continuous improvement and innovation, with a diverse range of products and services in orthopedics and beyond [4]

Alongside an evidence-based portfolio, Enovis will showcase how it’s “Redefining Every Step” with confidence-building education and a partnership that goes beyond the product; attendees invited to exclusive events. Enovis Featured Products at ACFAS 2025 Enovis Foot & Ankle will be featuring these products at ACFAS 2025, March 27-30, in Phoenix, Arizona. WILMINGTON, DE, March 25, 2025 (GLOBE NEWSWIRE) -- Enovis™ (NYSE: ENOV), a global medical technology innovator, will feature its expanding portfolio of f ...